Shima K, Chigasaki H, Seki K
Department of Neurosurgery, National Defense Medical College, Saitama.
Neurol Med Chir (Tokyo). 1990 Feb;30(2):109-12. doi: 10.2176/nmc.30.109.
The investigators assessed the effects of the opioid antagonist naloxone on anterior pituitary hormone release in hyperprolactinemic females with pituitary microadenoma (n = 6) and macroadenoma (n = 7). In those with microadenoma, intravenous bolus injection of naloxone significantly increased serum luteinizing hormone (LH) concentrations but had no significant effect on serum prolactin (PRL), follicle-stimulating hormone, and thyroid-stimulating hormone concentrations. In patients with macroadenoma, naloxone significantly decreased serum LH and serum PRL concentrations. The response of LH to naloxone differed considerably between the two groups of patients. The results suggest that LH and PRL secretion is influenced by changes in endogenous opiates and in gonadotropin-releasing hormone and PRL inhibitory factor due to hypothalamic dysfunction.
研究人员评估了阿片类拮抗剂纳洛酮对患有垂体微腺瘤(n = 6)和大腺瘤(n = 7)的高泌乳素血症女性垂体前叶激素释放的影响。在患有微腺瘤的女性中,静脉推注纳洛酮显著增加了血清促黄体生成素(LH)浓度,但对血清泌乳素(PRL)、促卵泡生成素和促甲状腺激素浓度没有显著影响。在患有大腺瘤的患者中,纳洛酮显著降低了血清LH和血清PRL浓度。两组患者中LH对纳洛酮的反应差异很大。结果表明,LH和PRL的分泌受内源性阿片类物质以及由于下丘脑功能障碍导致的促性腺激素释放激素和PRL抑制因子变化的影响。